Experts describe how the tumor microenvironment modulates clinical responses and how patient-derived ex vivo and engineered in vitro models can be used for pre-clinical immuno-oncology testing.
Dr. Nataliia Beztsinna and Dr. Marten Hornsveld describe the role of tumor microenvironment (TME) compartments in clinical responses, as well as ex vivo patient-derived tissue technologies capable of maintaining the native TME for pre-clinical testing. Complex in vitro models with the use of human stromal and immune co-cultures are discussed, together with the advantages of HCI to quantify intact tumor biology.
Key Topics Include:
- Examine the key components of the TME that affect immunotherapy responses. Discuss the main approaches to analyse the TME composition and the differences between ‘hot’ and ‘cold’ solid tumors
- Identify ex vivo assays capable of maintaining native human TME. Discuss the advantages of high content imaging assay on fresh patient tissue in 3D for deciphering complex immuno-oncology drug responses
- Comparison between in vitro based assays containing native TME or reconstituted TME
- How myeloid cells in the TME affect tumors and methods to study and target this compartment
- Advances in modelling the mesenchymal TME compartment in vitro and constructing pre-clinical mini-tumor platforms
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
Presenters
Associate Director / Head of 3D Ex vivo Patient Tissue Platform
Crown Bioscience
Dr. Nataliia Beztsinna has a MS degree in Biochemistry and PhD in Biology-Chemistry interface. She is experienced in confocal microscopy, high content imaging, 3D cell culture, organoids, molecular imaging, primary patient tissue cultures, in vitro and in vivo cancer models and tumor- targeted drug delivery nanosystems. Currently Nataliia is working as a Head of 3D Ex Vivo Patient Tissue (EVPT) Platform. Her responsibilties include managing a small team of highly-skilled scientists, ensuring high quality execution of customer projects, interactions, technical advising and quote design for potential customers as well as research and development activities dedicated to the growth of the EVPT Platform.
Senior Scientist, Oncology
Crown Bioscience
Dr. Marten Hornsveld is a molecular biologist that focuses on understanding and targeting molecular signal transduction in cancer. During his PhD program, he studied the role of PI3K-AKT signaling in breast cancer using a variety of mouse and cell based models. In his postdoctoral research he moved into the organoid technology field and worked on building representative organoid models for pancreatic cancer. This resulted in the establishment of a novel close-to-patient mini-tumor model that can be employed for both basic research and pre-clinical studies. A year ago, he switched gears and started as a senior scientist at Crown Bioscience. Here, he continues to work on building pre-clinical tumor models to facilitate rapid discovery of promising lead compounds in the oncology field.
Production Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology.
Additional Content From Crown Bioscience
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance
In this webinar, three experts discuss best practices for ensuring specimen integrity, leveraging biobanking for oncology breakthroughs, and enriching clinical data for translational research.
Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies
Learn how enhanced CDX models with humanized immune systems improve preclinical-to-clinical success in emerging immuno-oncology therapies.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.